Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lux-Breast 3: Afatinib in HER2+ Breast Cancer with Brain Metastases
NCT01441596Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2011
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of afatinib in HER2-positive breast cancer (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Patient Benefit Rate at 12 Weeks. Started Oct 2011; status: completed.
02
Drugs
afatinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01441596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01441596.